Comparative Pharmacology
Head-to-head clinical analysis: CONSENSI versus FENOLDOPAM MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONSENSI versus FENOLDOPAM MESYLATE.
CONSENSI vs FENOLDOPAM MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Consensi is a fixed-dose combination of amlodipine, a dihydropyridine calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Celecoxib inhibits prostaglandin synthesis via COX-2, reducing inflammation and pain.
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Adults: 0.25 mg/kg intravenously over 1 hour every 2 weeks.
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life of 12-15 hours for parent drug and 18-24 hours for active metabolite, allowing once-daily dosing.
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Primarily renal (70-80% as unchanged drug and active metabolite desmethyl-consensi); biliary/fecal: 15-20%.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Category C
Category C
Antihypertensive/NSAID Combination
Antihypertensive